Neuronal Pain Pathway Targeting Peripheral Hyperexcitability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain, particularly neuropathic pain associated with nerve injury, are ineffective due to the complex nature of the mammalian nervous system, and there is a need to understand the molecular mechanisms of long-term hyperexcitability in sensory neurons of the peripheral nervous system to develop targeted therapies.
Innovation Solution
A novel molecular pathway involving increased nitric oxide synthase activity leading to nitric oxide production, activation of guanylyl cyclase, and subsequent activation of protein kinase G, which is retrogradely transported to the neuron cell body to modulate pain-related gene expression, is discovered, allowing for the development of methods to inhibit long-term hyperexcitability and persistent pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for chronic pain are used, then they are administered systemically, but they are ineffective due to the complex nature of the mammalian nervous system and the blood-brain barrier
Solution Approach 1:
The patent extracts and targets the specific molecular pathway (NOS-GC-PKG-MAPK) within the complex nervous system. By identifying and isolating this particular signaling cascade in sensory neurons, the invention bypasses the need to treat the entire complex nervous system, thereby improving treatment effectiveness without being hindered by systemic complexity
Solution Approach 2:
The patent uses specific molecular intermediaries (nitric oxide, cGMP, PKG) to transmit the therapeutic effect from the administered compound to the target pathway. These molecular mediators enable precise targeting of the pain pathway while avoiding the blood-brain barrier, resolving the contradiction between effective delivery and system complexity
2Ease of operation
If current pain treatments are administered, then they are given systemically, but they cannot effectively target the peripheral nervous system due to the blood-brain barrier
Solution Approach 1:
The patent applies local quality by targeting specific sensory neurons in the peripheral nervous system rather than administering drugs systemically. The compound is designed to act locally on the NOS-GC-PKG-MAPK pathway in dorsal root ganglion neurons, achieving both ease of administration and high targeting accuracy by concentrating the effect where it is needed most
Solution Approach 2:
The patent employs retrograde axonal transport to copy the natural transport mechanism used by neurons to move materials from peripheral terminals back to the cell body. By designing the compound to hitchhike on this existing transport system, the invention achieves accurate targeting of peripheral neurons through simple systemic or local administration
3Reliability
If the molecular pathway is targeted in the peripheral nervous system, then the treatment addresses chronic pain at its origin, but it requires understanding complex molecular mechanisms
Solution Approach 1:
The patent segments the complex molecular pathway into discrete, targetable components: NOS (nitric oxide synthase), GC (guanylyl cyclase), PKG (protein kinase G), and MAPK (mitogen-activated protein kinase). By identifying and targeting specific enzymes and proteins within this cascade, the invention simplifies the complex molecular mechanism into manageable therapeutic targets while maintaining high treatment efficacy
Solution Approach 2:
The patent exploits parameter changes in the molecular pathway, specifically the conversion of GTP to cGMP by guanylyl cyclase, and the subsequent phosphorylation events in the PKG-MAPK cascade. By designing compounds that modulate these biochemical parameters (cGMP levels, phosphorylation states), the invention achieves reliable pain treatment by controlling key parameters in the pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This pathway provides a mechanism to effectively treat primary hyperalgesia by targeting the peripheral nervous system, avoiding the limitations of the blood-brain barrier and addressing chronic pain at its origin, thereby reducing subjective pain perception.
Implementation Method 1
an increase in nitric oxide synthase ('NOS') activity results in increased nitric oxide ('NO') production
Implementation Method 2
activates guanylyl cyclase ('GC'), thereby increasing levels of cyclic guanosine monophosphate ('cGMP')
Implementation Method 3
activation of protein kinase G ('PKG')
Implementation Method 4
which then is retrogradely transported along the axon to the neuron cell body
Implementation Method 5
where it phosphorylates mitogen-activated protein kinase-erk ('MAPKerk')
Data Source
AI summary
The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.